A Double Blind, Randomized, Placebo Controlled, Single-dose Escalation, First-time-in-human Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2012
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 04 Apr 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.